Validation Technologies, Inc. (VTI), an ISO 9001:2008 Certified Global Company, strives to maintain and inspire professional excellence by providing Validation, Commissioning, and Qualification (C&Q) Services to Pharmaceuticals, Biotechnology, Biologics, Medical Devices and FDA/Internationally regulated industries. We have the experience, expertise, and commitment to provide the superior service required to meet all of your validation and compliance needs.
We offer a full spectrum of services such as computer validation, cleaning validation, process validation, clean room certification, temperature mapping, process equipment and facility qualification, and much more. Dedication to quality, personalized support and the success of your projects are the foundation of our company.
Validation Technologies, Inc. will be attending the 24th Annual ISPE Boston Area Chapter Product Show on October at Gillette Stadium in Foxborough. Please stop by booth 2005 and meet our VTI team to inquire about our services. More information: ISPE Boston Product Show
David Vincent, CEO will be presenting at the 2015 IPA 11th Annual GMP Update Conference. Held in Montreal on October 7th-8th, the conference will provide attendees with insight and a plethora of information on quality, compliance, validation, and regulatory areas affecting the pharmaceutical, biopharmaceutical and allied industries. Our distinguished roster of speakers this year includes […]
David Vincent, CEO of VTI recently presented at the 6th annual EU Validation Week in Amsterdam, Netherlands on March 17-19, 2015. The presentation will provide the process of establishing the acceptance criteria to meet today’s regulatory environment. Additional information was provided by Dawn Tavalsky, on how to develop a three stage approach in setting acceptance criteria for cleaning process, including […]
In recent years, the subject of quality risk management has become a major focus of the Food and Drug Administration (FDA). On April 9-11 2002, the FDA held a public meeting in Washington, D.C. The purpose of the meeting was for the public to comment on the following three FDA concept papers: Premarketing Risk Assessment, […]